- Trade Name: Xofluza (Shionogi)
- Indications: Indicated for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours.
- Class: Polymerase acidic (PA) endonuclease inhibitor
- Half-life: 79.1 hours
- FDA Approval Date: 10/24/2018
- Clinically important, potentially hazardous interactions with:
Calcium Hydroxylapatite, Selenium, Zinc - Pregnancy: no available data
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
